Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine-Reference-Cited by-同舟云学术

Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine

Published:2020-01-01 Issue:1 Volume:9 Page:2245-2255
ISSN:2222-1751
Container-title:Emerging Microbes & Infections
language:en
Short-container-title:Emerging Microbes & Infections

Author:

Schloer Sebastian¹²,Brunotte Linda³²^ORCID,Goretzko Jonas¹²,Mecate-Zambrano Angeles³²,Korthals Nadia¹,Gerke Volker¹²,Ludwig Stephan³²^ORCID,Rescher Ursula¹²^ORCID

Affiliation:

1. Institute of Medical Biochemistry, Center for Molecular Biology of Inflammation, and “Cells in Motion” Interfaculty Centre, University of Muenster, Muenster, Germany

2. Interdisciplinary Centre for Clinical Research, University of Muenster, Muenster, Germany

3. Institute of Virology, Center for Molecular Biology of Inflammation, and “Cells in Motion” Interfaculty Centre, University of Muenster, Muenster, Germany

Funder

German Research Foundation

Interdisciplinary Center for Clinical Research

Münster Medical School

Innovative Medizinische Forschung

Publisher

Informa UK Limited

Subject

Virology,Infectious Diseases,Drug Discovery,General Medicine,Immunology,Microbiology,Parasitology,Epidemiology

Link

https://www.tandfonline.com/doi/pdf/10.1080/22221751.2020.1829082

Reference43 articles.